Davis Capital Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
Other funds holding SRPT
Davis Capital Management's SRPT Position: Q3 2026 in Review
Davis Capital Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 6 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #1011.
Davis Capital Management first reported a position in SRPT in Q2 2026 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.
- Davis Capital Management held 6 shares of Sarepta Therapeutics worth $109 as of Q3 2026.
- Davis Capital Management left its Sarepta Therapeutics share count unchanged in Q3 2026.
- Sarepta Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1011 holding.
- Davis Capital Management first reported a position in Sarepta Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 305 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.
Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.